Ovarian Function in Adolescents and Young Adults Undergoing Cancer Treatment: Biochemical and Ultrasound Marker Analysis

Overview

Journal Endocr Connect

Date 2025 Jan 31

PMID 39887687

Authors

Claudia Signorino

Erica Bencini

Annalisa Tondo

Perla Scalini

Angela Tamburini

Tommaso Casini

Iacopo Sardi

Stefano Stagi

Affiliations

Soon will be listed here.

Abstract

Objective: Gonadal dysfunction is a major late complication after cancer diagnosis and treatment. We aimed to study the prevalence of premature ovarian insufficiency (POI) and the potential reduction of ovarian reserve in a cohort of adolescent and young adult (AYA) patients undergoing cancer treatments, evaluating ovarian function and reserve markers. We also aimed to analyze how these markers are related to each other and to treatment-related risk factors.

Methods: We performed a retrospective study, including all female AYA patients undergoing cancer treatment during childhood or adolescence, who visited our pediatric gynecology outpatient clinic between January 1, 2018, and August 30, 2023. Serum levels of anti-Mullerian hormone (AMH) and follicle-stimulating hormone (FSH), antral follicle count (AFC) and mean ovarian volume were evaluated. The correlations between these markers and how their alterations are related to treatment-related risk factors were analyzed.

Results: The prevalence of POI in 95 patients was 18.9%. A significant positive correlation was observed between AMH levels and both AFC and ovarian volume. AMH was the most reliable serum marker for ovarian function in terms of POI. Independent risk factors for ovarian dysfunction in relation to all the markers analyzed were hematopoietic stem cell transplantation (HSCT) and high doses of alkylating agents (≥6000 mg/m2).

Conclusion: Gonadal dysfunction and infertility are quite common in AYA patients undergoing cancer treatment. High-dose alkylating agents and HSCT are the independent risk factors. AMH and FSH values, AFC and mean ovarian volume provide different but consistent information for closely monitoring patients after cancer treatment.

References

Wang S, Zhang Y, Mensah V, Huber 3rd W, Huang Y, Alvero R . Discordant anti-müllerian hormone (AMH) and follicle stimulating hormone (FSH) among women undergoing in vitro fertilization (IVF): which one is the better predictor for live birth?. J Ovarian Res. 2018; 11(1):60. PMC: 6048693. DOI: 10.1186/s13048-018-0430-z. View

Bresters D, Emons J, Nuri N, Ball L, Kollen W, Hannema S . Ovarian insufficiency and pubertal development after hematopoietic stem cell transplantation in childhood. Pediatr Blood Cancer. 2014; 61(11):2048-53. DOI: 10.1002/pbc.25162. View

Rosario R, Cui W, Anderson R . Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies. Reprod Fertil. 2022; 3(3):R147-R162. PMC: 9346327. DOI: 10.1530/RAF-22-0020. View

Green D, Nolan V, Goodman P, Whitton J, Srivastava D, Leisenring W . The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2013; 61(1):53-67. PMC: 3933293. DOI: 10.1002/pbc.24679. View

Fleming R, Seifer D, Frattarelli J, Ruman J . Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reprod Biomed Online. 2015; 31(4):486-96. DOI: 10.1016/j.rbmo.2015.06.015. View

Metzger M, Meacham L, Patterson B, Casillas J, Constine L, Hijiya N . Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013; 31(9):1239-47. PMC: 4500837. DOI: 10.1200/JCO.2012.43.5511. View

Sullivan S, Sarrel P, Nelson L . Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016; 106(7):1588-1599. PMC: 5137796. DOI: 10.1016/j.fertnstert.2016.09.046. View

Wasilewski-Masker K, Seidel K, Leisenring W, Mertens A, Shnorhavorian M, Ritenour C . Male infertility in long-term survivors of pediatric cancer: a report from the childhood cancer survivor study. J Cancer Surviv. 2014; 8(3):437-47. PMC: 4276596. DOI: 10.1007/s11764-014-0354-6. View

Jin H, Lee J, Park M, Park H . Gonadal Function in Female Adolescent and Young Adult Survivors of Childhood Cancer. Cancer Res Treat. 2023; 55(3):992-1000. PMC: 10372588. DOI: 10.4143/crt.2022.1518. View

10.

Shankar R, Dowlut-McElroy T, Dauber A, Gomez-Lobo V . Clinical Utility of Anti-Mullerian Hormone in Pediatrics. J Clin Endocrinol Metab. 2021; 107(2):309-323. PMC: 8764360. DOI: 10.1210/clinem/dgab687. View

11.

Nystrom A, Morse H, Nordlof H, Wiebe K, Artman M, Ora I . Anti-müllerian hormone compared with other ovarian markers after childhood cancer treatment. Acta Oncol. 2018; 58(2):218-224. DOI: 10.1080/0284186X.2018.1529423. View

12.

Boltezar L, Pintaric K, Novakovic B . Fertility in young patients following treatment for Hodgkin's lymphoma: a single center survey. J Assist Reprod Genet. 2015; 33(3):325-333. PMC: 4785158. DOI: 10.1007/s10815-015-0636-6. View

13.

Jiao X, Meng T, Zhai Y, Zhao L, Luo W, Liu P . Ovarian Reserve Markers in Premature Ovarian Insufficiency: Within Different Clinical Stages and Different Etiologies. Front Endocrinol (Lausanne). 2021; 12:601752. PMC: 8015703. DOI: 10.3389/fendo.2021.601752. View

14.

van den Berg M, Overbeek A, Lambalk C, Kaspers G, Bresters D, van den Heuvel-Eibrink M . Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Hum Reprod. 2018; 33(8):1474-1488. DOI: 10.1093/humrep/dey229. View

15.

La Marca A, Sunkara S . Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2013; 20(1):124-40. DOI: 10.1093/humupd/dmt037. View

16.

Roesner S, Hecht S, Germeyer A, Strowitzki T . Successful in vitro maturation for urgent fertility preservation despite hormonal contraception by continuous progestin application. Gynecol Endocrinol. 2019; 35(4):298-300. DOI: 10.1080/09513590.2018.1531985. View

17.

Brancati S, Gozzo L, Longo L, Vitale D, Russo G, Drago F . Fertility Preservation in Female Pediatric Patients With Cancer: A Clinical and Regulatory Issue. Front Oncol. 2021; 11:641450. PMC: 8008167. DOI: 10.3389/fonc.2021.641450. View

18.

Haavisto A, Wettergren L, Lampic C, Lahteenmaki P, Jahnukainen K . Premature ovarian insufficiency and chance of pregnancy after childhood cancer: A population-based study (the Fex-Can study). Int J Cancer. 2023; 153(3):644-653. DOI: 10.1002/ijc.34541. View

19.

Ben Charif A, Bouhnik A, Courbiere B, Rey D, Preau M, Bendiane M . Sexual health problems in French cancer survivors 2 years after diagnosis-the national VICAN survey. J Cancer Surviv. 2015; 10(3):600-9. DOI: 10.1007/s11764-015-0506-3. View

20.

. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020; 114(6):1151-1157. DOI: 10.1016/j.fertnstert.2020.09.134. View